The Engineered Lysin, CF-370, is Active Against Antibiotic-Resistant Gram-Negative Pathogens In vitro and Synergizes with Meropenem in Experimental Pseudomonas aeruginosa Pneumonia

By sjmartinez • February 18, 2024

Sauve K, Watson A, Oh JT, Swift S, Vila-Farres X, Abdelhady W, Xiong YQ, LeHoux D, Woodnutt G, Bayer AS, Schuch R. The Engineered Lysin, CF-370, is Active Against Antibiotic-Resistant Gram-Negative Pathogens In vitro and Synergizes with Meropenem in Experimental Pseudomonas aeruginosa Pneumonia. J Infect Dis. 2024 Feb 15:jiae027. doi: 10.1093/infdis/jiae027. Epub ahead of print. PMID: 38366561.

Tags: ESKAPE pathogens, Harbor UCLA, Infectious Diseases, Lysin, multidrug-resistance, pneumonia, pseudomonas aeruginosa, Publications, synergy

Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statement

Leboulleux S, Boucai L, Busaidy N, Durante C, Fagin JA, Fazeli S, Gianoukakis AG, Haugen BR, Kang H, Konda B, Laetsch TW, Locati L, Ryder[...]

Heterozygous NTHL1 variant in a breast cancer survivor with malignant pleural effusion revealing metastatic colon adenocarcinoma

Lewis LK, Varda MM, McCann KE, Huang C. Heterozygous NTHL1 variant in a breast cancer survivor with malignant pleural effusion revealing metastatic colon adenocarcinoma. BMJ[...]

CTA-Derived Plaque Characteristics and Risk of Acute Coronary Syndrome in Patients With Coronary Artery Calcium Score of Zero: Insights From the ICONIC Trial

Jonas RA, Nurmohamed NS, Crabtree TR, Aquino M, Jennings R, Choi AD, Lin FY, Lee SE, Andreini D, Bax J, Cademartiri F, Chinnaiyan K, Chow[...]